Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

DIABIL-2

Financiado

Cerrado

Ultra low dose of IL 2 for the treatment of recently diagnosed type 1 diabetes

Concept The discovery of regulatory T cells (Tregs) has revolutionized our understanding of autoimmune diseases. As T1D is caused by the failure of Tregs to block autoimmune destruction of pancreatic ß-cells, Treg stimulation has... ver más

31/03/2019

ASSISTANCE PUBLIQU...

8M€

Presupuesto del proyecto: 8M€

Líder del proyecto

ASSISTANCE PUBLIQUE HOPITAUX DE PARIS No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 7 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2019-03-31 No tenemos la información de la convocatoria

0% 78% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

7 Participantes

ASSISTANCE PUBLIQUE HOPITAUX...

0.00€ | Lider

INSERM TRANSFERT SA

N.D. | Participante

KANTONSSPITAL BASEL

N.D. | Participante

ILTOO PHARMA

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

HONEYDIAB-8 Characterization of islet specific CD8 T cells in the honeym... 183K€ Cerrado

SAF2011-29319 ANALISIS FUNCIONAL DE CELULAS T REGULADORAS Y DE CELULAS B A... 85K€ Cerrado

SAF2010-18548 ANALISIS FUNCIONAL DE CELULAS T REGULADORAS Y DE CELULAS B A... 42K€ Cerrado

RTI2018-097414-B-I00 MECANISMOS DE TOLERANCIA EN LA DIABETES DE TIPO 1: PROCESAMI... 182K€ Cerrado

SAF2010-21977 EFECTO DE LAS CITOQUINAS PROINFLAMATORIAS SOBRE LA CAPACIDAD... 18K€ Cerrado

TR1 CELLS Molecular mechanisms leading to generation of Type 1 regulat... 272K€ Cerrado

Líder del proyecto

ASSISTANCE PUBLIQUE HOPITAUX DE PARIS No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 8M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Concept The discovery of regulatory T cells (Tregs) has revolutionized our understanding of autoimmune diseases. As T1D is caused by the failure of Tregs to block autoimmune destruction of pancreatic ß-cells, Treg stimulation has the potential to stop the process, preserve ß-cells’ insulin secretion, and likewise prevent or delay disease progression and improve clinical outcome for patients. Background Low-dose interleukin-2 (ld-IL2) was recently shown to stimulate Tregs without stimulating effector T cells. In NOD mice, ld-IL2 can prevent and cure T1D. In humans, (i) we showed that ld-IL2 is safe, induces Tregs and is associated with clinical improvement in patients with autoimmune vasculitis; and (ii) we performed a dose-finding study in T1D to define an ultra-low dose IL-2 (uld-IL2) that is well tolerated and induces Tregs’ numbers and functionality. With this strong background – a well defined mechanism of action; proof of concept in NOD mice; proof of principle in a clinical trial with another autoimmune disease; safety and activity/efficacy data in T1D – we propose a phase-II clinical trial testing the efficacy of uld-IL2 for preserving ß-cells. Method This will be a double-blind randomised placebo-controlled, age-stratified (6-35 year), multicentre European trial assessing efficacy and safety of uld-IL2 (0.5M IU/m2/day with a maximum of 1 MIU/m2/day for adult patients) in 138 recently-diagnosed T1D patients. Our methodology strictly follows the Immunology of Diabetes Society consensus recommendations and European regulatory guidelines. The primary end-point is the change from baseline of AUC C-peptide during a mixed meal test at 1 year. The trial is precisely and conservatively powered to detect an effect size of d=0.5. Impacts If successful, this trial will have profound impacts for the management of patients with recently-diagnosed T1D, their families and EU economy. It will be a milestone towards preventing T1D in people at risk of this increasingly common childhood disease.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores